Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Clover Health Investments heads into its November earnings with short sellers adding positions into a stock that has nearly doubled this year, while the executives selling those shares are doing so on pre-arranged plans rather than discretionary conviction.
Short interest has risen meaningfully this week. It climbed to 6.0% of the free float on October 8, up 6.3% in a single day and 4.6% over the week, with the absolute share count now at roughly 25.6 million. The rebuild is notable because it comes against a backdrop of an 8.3% weekly gain and a 7.6% monthly advance to $4.58. Critically, the borrow market is in no way strained by this activity. Availability is running at around 820% of short interest, meaning there are more than eight shares available to lend for every one already borrowed, well clear of any squeeze territory. Cost to borrow is only 0.50%, up around 8% on the week but still near its lowest range of the year. The ORTEX short score of 47.3 is broadly neutral, and the short-score history has been remarkably flat over the past two weeks, giving no directional signal from the squeeze-risk side.
Options traders are tilting very slightly more defensive. The put/call ratio has edged up to 0.27, roughly one standard deviation above its 20-day average of 0.25. That is a long way from the 52-week high of 0.54, and the overall picture from options is one of muted caution rather than active hedging. The primary signal from positioning is that shorts are adding but have no urgency, and buyers of protection are barely registering.
The insider story is worth separating from the noise. The 90-day net selling is $4.3 million across roughly 948,000 net shares, but every material sale in the visible record is flagged as under a 10b5-1 pre-arranged plan. CEO Andrew Toy sold 318,806 shares on October 1 for just over $1.3 million, and the CEO of the Medicare Advantage division, Jamie Reynoso, has filed a series of smaller plan-driven sales through October. Pre-planned disposals carry less informational weight than discretionary sells, and two directors received share grants on September 30, both classified as awards rather than open-market purchases. The net signal is plan-driven selling into strength, not a discretionary exit.
The Street is cautiously constructive. The consensus is a buy, with a mean price target of $5.375 against the current $4.58, implying around 17% to that level. The most recent analyst action came from UBS in early August, where Jonathan Yong raised his target to $5.00 while staying at Neutral. Canaccord Genuity's Richard Close has been consistently bullish, raising his target twice over the summer to $5.50. Both firms have been steadily lifting targets since the spring. The bull case centres on Clover Assistant's effectiveness in chronic disease management and improving unit economics. The bear case flags a potential star-rating downgrade and flat CMS advance rates in 2027 as the clearest earnings risks. The EV/EBITDA multiple has contracted about 3 turns over the past 30 days to roughly 22x, which is a modest re-rating lower even as the stock has risen, suggesting earnings estimates have risen faster than price. The 90-day EPS momentum factor ranks in the 98th percentile, the strongest single factor score in the snapshot.
The last earnings print on August 5 produced a 9.1% one-day gain and a 6.3% five-day advance, the only recent data point available. The next event is November 4, giving around 26 days from today. With retail attention below its own 90-day average on Wikipedia traffic metrics, the stock's recent move appears institutional rather than crowd-driven. Peer performance this week was mixed: ALHC gained 12.5% to lead the group, while HUM fell 2.4% and ASTH dropped 3.4%, making CLOV's 8.3% weekly gain a clear outperformer within its sector cohort.
The next focal point is the November 4 print, where the debate will centre on whether the 2027 Medicare Advantage rate and star-rating risks are already priced into a stock that has run 94% year-to-date, or whether improving unit economics justify the current PE of around 31x.
See the live data behind this article on ORTEX.
Open CLOV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
